Physician profile
Sameer Chadha
NPI 1164736211
$132,421.77
in general payments reported to CMS, 2019-2025
29 companies · $30K in 2025
The $30K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $367 · 2021: $8,744 · 2022: $31K · 2023: $31K · 2024: $31K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $90K · Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $90,000.00 |
| Food and Beverage | $2,201.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $128,250.00 | 2021-2025 | Auryon Laser System 100-120 Vac |
| Abiomed | $842.93 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $357.02 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $343.16 | 2019-2023 | Xarelto |
| Kestra Medical Technology Services, INC. | $330.77 | 2024-2025 | Assure Wcd |
| Amgen INC. | $289.29 | 2020-2023 | Repatha |
| Abbott Laboratories | $246.77 | 2019-2025 | Ensite Precision |
| Medtronic, INC. | $229.56 | 2023 | Resolute Onyx |
| Glaxosmithkline, LLC. | $145.15 | 2019 | |
| Nuwellis, INC. | $142.87 | 2021 | |
| Medtronic Vascular, INC. | $138.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.47 | 2022-2025 | Jardiance |
| Cvrx, INC. | $129.00 | 2022-2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $126.09 | 2021-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $124.97 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $107.67 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $97.87 | 2022 | |
| Baxter Healthcare | $78.10 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Impulse Dynamics (USA) INC. | $56.98 | 2024 | Optimizer |
| Novartis Pharmaceuticals Corporation | $54.36 | 2019-2020 | |
| Esperion Therapeutics, INC. | $36.67 | 2020-2022 | |
| Cardiovascular Systems INC. | $29.69 | 2019 | |
| Bardy Diagnostics, INC. | $25.00 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $22.77 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $20.73 | 2022 | |
| Scpharmaceuticals INC. | $19.54 | 2024 | |
| Boston Scientific Corporation | $17.17 | 2020 | |
| Pfizer INC. | $13.62 | 2022 | |
| Livanova USA, INC. | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Chadha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.